Quantitative analysis of hepatitis D virus RNA and hepatitis B surface antigen serum levels in chronic delta hepatitis improves treatment monitoring

Antiviral Therapy

Volumn 12, Issue 3, 2007, Pages 381-388

  Manesis, Emanuel K ^a   Schina, Maria ^a   Le Gal, Frédéric ^b   Agelopoulou, Olga ^a   Papaioannou, Christos ^a   Kalligeros, Constantine ^c   Arseniou, Vaios ^c   Manolakopoulos, Spilios ^d   Hadziyannis, Emilia S ^a   Gault, Elyanne ^b   Koskinas, John ^a   Papatheodoridis, George ^a   Archimandritis, Athanasios J ^a  

^a HIPPOKRATION HOSPITAL   (Greece)

^b UNIVERSITÉ PARIS 13   (France)

^c Hepatology Service   (Greece)

^d IASO GENERAL HOSPITAL   (Greece)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA2B INTERFERON; HEPATITIS B SURFACE ANTIGEN; HEPATITIS B(E) ANTIGEN; LAMIVUDINE; VIRUS DNA; VIRUS RNA;

ADOLESCENT; ADULT; AGED; ARTICLE; BLOOD LEVEL; CHRONIC HEPATITIS; CONTROLLED STUDY; DELTA AGENT HEPATITIS; DRUG EFFICACY; DRUG HYPERSENSITIVITY; DRUG MECHANISM; DRUG WITHDRAWAL; FEMALE; FOLLOW UP; HEPATITIS B VIRUS; HEPATITIS DELTA VIRUS; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTIPLE CYCLE TREATMENT; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; RETROSPECTIVE STUDY; VIRUS REPLICATION;

ADOLESCENT; ADULT; ANTIVIRAL AGENTS; DNA, VIRAL; FEMALE; HEPATITIS B SURFACE ANTIGENS; HEPATITIS B VIRUS; HEPATITIS D, CHRONIC; HEPATITIS DELTA VIRUS; HUMANS; INTERFERON ALFA-2B; LAMIVUDINE; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; RNA, VIRAL; TIME FACTORS; TREATMENT OUTCOME;

EID: 34249078916     PISSN: 13596535     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (42)

1. Hoofnagle JH. Type D (delta) hepatitis. JAMA 1989; 261:1321-1325.
2. Rizzetto M, Durazzo M. Hepatitis delta virus (HDV) infections. Epidemiological and clinical heterogeneity. J Hepatol 1991; 13 Suppl 4:S116-S118.
3. Farci P. Delta hepatitis: an update. J Hepatol 2003; 39 Suppl 1:S212-S219.
4. Taylor JM. Hepatitis delta virus. Virology 2006; 344:71-76.
5. Niro G, Rosina F, Rizzetto M. Treatment of hepatitis D. J Viral Hepat 2005; 12:2-9.
6. Lau JY, King R, Tibbs CJ, et al. Loss of HBsAg with interferon-α therapy in chronic hepatitis D virus infection. J Med Virol 1993; 39:292-296.
7. Battegay M, Simpson LH, Hoofnagle JH, Sallie R, Di Bisceglie AM. Elimination of hepatitis delta virus infection after loss of hepatitis B surface antigen in patients with chronic delta hepatitis. J Med Virol 1994; 44:389-392.
8. Lau DT, Kleiner DE, Park Y, Di Bisceglie AM, Hoofnagle JH. Resolution of chronic delta hepatitis after 12 years of interferon α therapy. Gastroenterology 1999; 117:1229-1233.
9. Farci P, Mandas A, Coiana A, et al. Treatment of chronic hepatitis D with interferon α-2a. N Engl J Med 1994; 330:88-94.
10. Farci P, Roskams T, Chessa L, et al. Long-term benefit of interferon α therapy of chronic hepatitis D: regression of advanced hepatic fibrosis. Gastroenterology 2004; 126:1740-1749.
11. Malaguarnera M, Restuccia S, Pistone G, Ruello P, Giugno I, Trovato BA. A meta-analysis of interferon-α treatment of hepatitis D virus infection. Pharmacotherapy 1996; 16:609-614.
12. Rosina F, Pintus C, Meschievitz C, Rizzetto M. A randomized controlled trial of a 12-month course of recombinant human interferon-alpha in chronic delta (type D) hepatitis: A multicenter Italian study. Hepatology 1991; 13:1052-1056.
13. Di Marco V, Giacchino R, Timitilli A, et al. Long-term interferon-α treatment of children with chronic hepatitis delta: a multicentre study. J Viral Hepat 1996; 3:123-128.
14. Erhardt A, Gerlich W, Starke C, et al. Treatment of chronic hepatitis delta with pegylated interferon-α2b. Liver Int 2006; 26:805-810.
15. Ferenci P, Formann E, Romeo R. Successful treatment of chronic hepatitis D with a short course of peginterferon α-2a. Am J Gastroenterol 2005; 100:1626-1627.
16. Lau DT, Doo E, Park Y, et al. Lamivudine for chronic delta hepatitis. Hepatology 1999; 30:546-549.
17. Niro GA, Ciancio A, Tillman HL, et al. Lamivudine therapy in chronic delta hepatitis: a multicentre randomized-controlled pilot study. Aliment Pharmacol Ther 2005; 22:227-232.
18. Wolters LM, van Nunen AB, Honkoop P, et al. Lamivudine-high dose interferon combination therapy for chronic hepatitis B patients co-infected with the hepatitis D virus. J Viral Hepat 2000; 7:428-434.
19. Yurdaydin C, Bozkaya H, Gurel S, et al. Famciclovir treatment of chronic delta hepatitis. J Hepatol 2002; 37:266-271.
20. Gunsar F, Akarca US, Ersoz G, et al. Two-year interferon therapy with or without ribavirin in chronic delta hepatitis. Antivir Ther 2005; 10:721-726.
21. Bordier BB, Ohkanda J, Liu P, et al. In vivo antiviral efficacy of prenylation inhibitors against hepatitis delta virus. J Clin Invest 2003; 112:407-414.
22. Taylor JM. Therapy for HDV! Hepatology 2003; 38:1581-1582.
23. Casey J, Cote PJ, Toshkov IA, et al. Clevudine inhibits hepatitis delta virus viremia: a pilot study of chronically infected woodchucks. Antimicrob Agents Chemother 2005; 49:4396-4399.
24. Samuel D, Zignego AL, Reynes M, et al. Long-term clinical and virological outcome after liver transplantation for cirrhosis caused by chronic delta hepatitis. Hepatology 1995; 21:333-339.
25. Canbakan B, Senturk H, Tabak F, et al. Efficacy of interferon α-2b and lamivudine combination treatment in comparison to interferon α-2b alone in chronic delta hepatitis: a randomized trial. J Gastroenterol Hepatol 2006; 21:657-663.
26. Yamashiro T, Nagayama K, Enomoto N, et al. Quantitation of the level of hepatitis delta virus RNA in serum, by real-time polymerase chain reaction - and its possible correlation with the clinical stage of liver disease. J Infect Dis 2004; 189:1151-1157.
27. Le Gal F, Gordien E, Affolabi D, et al. Quantification of hepatitis delta virus RNA in serum by consensus real-time PCR indicates different patterns of virological response to interferon therapy in chronically infected patients. J Clin Microbiol 2005; 43:2363-2369.
28. van Helden J, Denoyel G, Karwowska S, et al. Performance of hepatitis B assays on the Bayer ADVIA Centaur Immunoassay System. Clin Lab 2004; 50:63-73.
29. Deguchi M, Yamashita N, Kagita M, et al. Quantitation of hepatitis B surface antigen by an automated chemilluminescent microparticle immunoassay. J Virol Methods 2004; 115:217-222.
30. Pawlotsky JM. Hepatitis B virus (HBV) DNA assays (methods and practical use) and viral kinetics. J Hepatol. 2003; 39 Suppl 1:S31-S35.
31. Ishak K, Baptista A, Bianchi L, et al. Histological grading and staging of chronic hepatitis. J Hepatol 1995; 22:696-699.
32. Ganem D. Assembly of hepadnaviral virions and subviral particles. In Hepadnaviruses: Molecular Biology and Pathogenesis, vol. 168 1991; pp 61-84. Edited by WS Mason & C Seeger. Berlin: Springer-Verlag.
33. Borghesio E, Rosina F, Smedile A, et al. Serum immunoglobulin M antibody to hepatitis D as a surrogate marker of hepatitis D in interferon-treated patients and in patients who underwent liver transplantation. Hepatology 1998; 27:873-876.
34. Manesis EK, Hadziyannis SJ. Interferon α treatment and retreatment of hepatitis B e antigen-negative chronic hepatitis B. Gastroenterology 2001; 121:101-109.
35. Marcellin P, Lau GK, Bonino F, et al. Peginterferon α-2a alone, lamivudine alone, and the two in combination in patients with HBeAg-negative chronic hepatitis B. N Engl J Med 2004; 351:1206-1217.
36. Ilan Y, Klein A, Taylor J, Tur-Kaspa R. Resistance of hepatitis delta virus replication to interferon-α treatment in transfected human cells. J Infect Dis 1992; 166:1164-1166.
37. Hartwig D, Schoeneich L, Greeve J, et al. Interferon-α stimulation of liver cells enhances hepatitis delta virus RNA editing in early infection. J Hepatol. 2004; 41:667-672.
38. Chulanov VP, Shipulin GA, Schaefer S, Gerlich WH. Kinetics of HBV DNA and HBsAg in acute hepatitis B patients with and without coinfection by other hepatitis viruses. J Med Virol 2003; 69:313-323.
39. Thomas H, Foster G, Platis D. Mechanisms of action of interferon and nucleoside analogues. J Hepatol 2003; 39:S93-S98.
40. Guidotti LG, Rochford R, Chung J, Shapiro M, Purcell R, Chisari FV. Viral clearance without destruction of infected cells during acute HBV infection. Science 1999; 284:825-829.
41. Kohmoto M, Enomoto M, Tamori A, et al. Quantitative detection of hepatitis B surface antigen by chemiluminescent microparticle immunoassay during lamivudine treatment of chronic hepatitis B virus carriers. J Med Virol 2005; 75:235-239.
42. Manesis EK, Hadziyannis ES, Angelopoulou OP, Hadziyannis ST. Prediction of treatment-related HBsAg loss in HBeAg-negative chronic hepatitis B: a clue from serum HBsAg levels. Antivir Ther 2007; 12:73-82.